Drugs.com

AUGUST 1, 2024

1, 2024 -- A next-generation nasal vaccine for COVID-19 appears to do what injectable vaccines can’t -- actually stop the spread of the virus from person to person.Hamsters that received the nasal vaccine didn’t pass the virus on to. THURSDAY, Aug.

Vaccine 276

Vaccine Trials Virus 276

Drugs.com

OCTOBER 6, 2023

announced Wednesday that it has seen positive early results with a new vaccine that would guard against four strains of flu plus COVID-19. In interim findings from a Phase 1/2 trial, the vaccine showed both a. THURSDAY, Oct. 5, 2023 -- Moderna Inc.

Vaccine 278

Vaccine Trials 278

Science Daily: Pharmacology News

OCTOBER 17, 2024

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile vaccine was found to protect against C. difficile vaccine was found to protect against C. difficile or C. In animal models, this first mRNA-LNP C.

Vaccine 321

Vaccine Immune Response Clinical Trials Trials 321

Drugs.com

SEPTEMBER 4, 2024

4, 2024 -- Current vaccines against mpox were designed to fight an older, rarer cousin of the virus, smallpox.Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a. WEDNESDAY, Sept.

Vaccine 246

Vaccine Trials Virus Research 246

Drugs.com

APRIL 8, 2024

MONDAY, April 8, 2024 -- A pancreatic cancer vaccine has continued to protect a small group of patients from their cancer coming back, three years after receiving the jab, a new study says.Eight patients have not had their pancreatic cancer recur.

Vaccine 278

Vaccine Trials 278

Science Daily: Pharmacology News

FEBRUARY 5, 2025

Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.

Vaccine 285

Vaccine Immune Response Clinical Trials Trials 285

Drugs.com

APRIL 9, 2024

TUESDAY, April 9, 2024 -- A custom-made anti-tumor vaccine added to standard immunotherapy was twice as likely to shrink liver cancer as when a patient received immunotherapy alone, a new study shows.The vaccine could help liver cancer patients.

Vaccine 246

Vaccine Trials 246

Drugs.com

JANUARY 9, 2024

9, 2024 -- Patients with the most common form of pancreatic cancer could benefit from an experimental therapeutic vaccine, a small new clinical trial shows.The vaccine, called ELI-002 for now, is targeted to what are known as. TUESDAY, Jan.9,

Vaccine 246

Vaccine Clinical Trials Trials 246

Drug Discovery Today

DECEMBER 22, 2020

First in human trials for vaccine candidate with the potential to confer long-term immunity

Clinical Trials 192

Clinical Trials Vaccine Trials 192

Drugs.com

FEBRUARY 6, 2025

6, 2025 -- A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial. THURSDAY, Feb.

Vaccine 162

Vaccine Trials Research 162

BioPharma Drive: Drug Pricing

MAY 10, 2024

The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.

Vaccine 274

Vaccine FDA Regulations Trials 274

PPD

JUNE 24, 2024

In the realm of vaccine development, mega trials — studies enrolling 5,000 subjects or more — have been instrumental in the fight against many pathogens, including influenza, rotavirus, malaria, RSV and most recently in the rapid development of vaccines against COVID-19.

Vaccine 97

Vaccine Trials Clinical Trials Laboratories 97

Fierce BioTech

FEBRUARY 26, 2025

Redefining vaccine trial recruitment Clinical trials are vital for developing safe and effective vaccines, but their success relies on overcoming recruitment challenges and ensuring diverse study cohorts. Discover innovative, data-driven recruitment strategies to ensure diverse, efficient, and high-quality vaccine trials.

Vaccine 52

Vaccine Trials Clinical Trials Clinical Research 52

Drug Discovery Today

APRIL 15, 2021

First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial the vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit). 176 volunteers will participate in the clinical trial the safety and immune response read-outs expected in Q2 2021

Clinical Trials 113

Clinical Trials Vaccine Trials Immune Response 113

SCIENMAG: Medicine & Health

AUGUST 3, 2023

The Access to Advanced Health Institute Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine Through a Phase 1 Clinical Trial Credit: Delaney Brown Photography The Access to Advanced Health Institute Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine Through a Phase (..)

RNA 93

RNA Clinical Trials Vaccine Trials 93

Drug Discovery Today

JANUARY 22, 2020

A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines’ effectiveness. The analysis, published by the Journal of the Royal Society of Medicine, assessed 12 published Phase 2 and 3 randomised controlled efficacy trials of the HPV vaccines Cervarix and Gardasil.

Vaccine 100

Vaccine Clinical Trials Trials 100

DrugBank

MARCH 12, 2025

The COVID-19 pandemic brought mRNA to global prominence by developing highly effective vaccines by Moderna and Pfizer-BioNTech. However, mRNA technology has introduced new possibilities, particularly in developing personalized cancer vaccines and combination therapies. Another challenge is the potential for unintended immune responses.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . Each patient was given two 100 microgram doses of the vaccine 28 days apart. There is hope that Moderna’s vaccine could be available by early 2021. .

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

The Pharma Data

AUGUST 14, 2020

Professor Alexander Chuchalin has quit the Russian Health Ministry’s ethics council due to the quick approval process for the country’s coronavirus vaccine. Many countries have criticised Russia pursuit for a COVID-19 cure, which has skipped Phase 3 trials before giving the vaccine regulatory approval. Safety always comes first.

Vaccine 87

Vaccine Doctors Clinical Trials Trials 87

Drug Discovery Today

JULY 28, 2020

Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

Vaccine 100

Vaccine Clinical Trials Research DNA 100

Fierce BioTech

JUNE 12, 2024

By Ayako Wakatsuki Pedersen, SVP of Translational Research at IO Biotech | Historically, most cancer vaccine trials have fallen short. What is the potential of new vaccines that can dismantle cancer cells' defenses?

Vaccine 75

Vaccine Treatment Trials Research 75

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. The trial on 10,000 people will now see if the vaccine can prevent people getting ill. Some of the vaccines being developed for Covid-19 use either completely new or barely proven technologies. .

Vaccine 52

Vaccine Trials Immune Response Virus 52

SCIENMAG: Medicine & Health

JUNE 12, 2023

Peer-reviewed / Randomised Controlled Trial / People Study of healthy US adults found that a single dose of the VLA1553 vaccine candidate was generally safe, well tolerated and provokes an immune response.

Immune Response 66

Immune Response Vaccine Trials Disease 66

The Pharma Data

OCTOBER 22, 2020

COVID-19 Vaccine Trial Enrolls 30,000. 22, 2020 — The first company to start a phase 3 trial of a COVID-19 vaccine reached its target of enrolling 30,000 participants, CNN reported Thursday. Half of the participants were given the vaccine and half received a placebo. trial in August. Professional.

Vaccine 52

Vaccine Trials FDA Marketing 52

SCIENMAG: Medicine & Health

SEPTEMBER 15, 2023

Enrollment in a Phase 1 trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.

Vaccine 52

Vaccine Clinical Trials Trials Disease 52

The Pharma Data

AUGUST 7, 2020

AstraZeneca has signed its first deal in China to produce and deliver its vaccine candidate against COVID-19 in the country, partnering up with manufacturing firm Shenzhen Kangtai Biological Products. The agreement also leaves the door open for collaboration between the two firms on the delivery of the vaccine to other global markets.

Vaccine 88

Vaccine Trials Marketing Production 88

The Pharma Data

SEPTEMBER 14, 2020

. AstraZeneca has confirmed that clinical trials assessing its Oxford University partnered coronavirus vaccine AZD1222 have resumed in the UK, following a green light by the Medicines Health Regulatory Authority (MHRA). Source link.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

OCTOBER 26, 2020

COVID-19 Vaccine Trials. 26, 2020 — Drugmakers AstraZeneca and Johnson & Johnson are ready to resume paused COVID-19 vaccine trials after health scares, CNN reported. The AstraZeneca trial was stopped in early September, and the Johnson & Johnson trial was paused earlier this month.

Vaccine 52

Vaccine Trials Government Drugs 52

The Pharma Data

DECEMBER 17, 2020

COVID-19 vaccine developers are faced with an ethical quandary — whether to let phase 3 trial participants become “unblinded” and to receive authorized vaccines as they become available, which could hinder the collection of meaningful trial data. Pfizer, which has received emergency approvals in the U.S.

Vaccine 52

Vaccine Trials Long-Term Care Facilities FDA 52

The Pharma Data

SEPTEMBER 2, 2020

. Sanofi and GSK have begun a Phase I/II clinical trial testing their adjuvanted COVID-19 vaccine in healthy adults. The vaccine candidate, developed in partnership by the firms, is based on the recombinant protein-based technology used in Sanofi’s seasonal influenza vaccines and GSK’s pandemic adjuvant technology.

Vaccine 52

Vaccine Trials Immune Response Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. TUESDAY, Dec. 8 in The Lancet.

Vaccine 52

Vaccine Trials Immune Response RNA 52

Eye on FDA

SEPTEMBER 10, 2020

Vaccines for COVID-19 are the focus of the moment – politically and scientifically speaking. Scientifically, there was the big news that a vaccine trial had experienced a serious adverse event bringing a pause to bear in its continuation, likely throwing further cold water on the political side of the equation.

Vaccine 82

Vaccine Research Government Science 82

The Pharma Data

NOVEMBER 2, 2020

German biopharma company CureVac announced yesterday that its COVID-19 vaccine hopeful generated immune responses and was generally well-tolerated in phase 1 trial participants, lending support for a pivotal trial before year’s end. Source link.

Vaccine 52

Vaccine Trials Immune Response Research 52

The Pharma Data

NOVEMBER 19, 2020

Russia’s Gamaleya Research Institute has reportedly resumed dosing in a phase 3 trial evaluating its COVID-19 vaccine, Sputnik V., but a Russian government spokesperson denies that the study was ever paused. Source link.

Vaccine 52

Vaccine Trials Government Research 52

The Pharma Data

SEPTEMBER 9, 2020

Global trials for AstraZeneca’s much-hyped COVID-19 vaccine, currently in development in partnership with the University of Oxford, have been halted after an unexplained illness was identified in one of the participants. In large trials illnesses will happen by chance but must be independently reviewed to check this carefully.

Vaccine 52

Vaccine Trials Government Treatment 52

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada. Conor Kavanagh.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52